Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial
Valneva SE (NASDAQ: VALN) has
Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments?
The demand for monoclonal antibody treatments to help in the recovery of COVID-19 patients has outpaced the supply, and this situation runs the risk of becoming more acute as federal regulators consider whether to limit the authorization of certain treatments that have yet to show their efficacy in mitigating the fast-spreading omicron variant.
Lower COVID-19 Vaccine Sales Estimated Amid Less Severe Omicron Variant: Bloomberg
According to an analytics firm, Airfinity Ltd, evidence that omicron causes less-severe disease than earlier COVID-19 variants is expected to lower the growth in vaccine sales this year.
AstraZeneca Rolls Out “Unprecedented’ Three Year Survival Data For Imfinzi/Treme Combo In Liver Cancer
A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab)
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference.
The Daily Biotech Pulse: Adagio’s Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Here's a roundup of top developments in the biotech space over the last 24 hours:
AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US
AstraZeneca Plc (NASDAQ: AZN) said the U.S.
AstraZeneca’s COVID-19 Vaccine Booster Against Omicron, Delta – New Data Supports Use
AstraZeneca Plc (NASDAQ: AZN) has
AstraZeneca and Scorpion Therapeutics Enter Agreement to Discover, Develop and Commercialize Novel Cancer Treatments Against Undruggable Targets; Scorpion to Receive an Upfront Cash Payment of $75M, Plus Potential Milestone Payments, Royalties
AstraZeneca has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialise precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.